Use of b7rp1 antagonists in ige-mediated disorders

Details Use of b7rp1 antagonists in ige-mediated disorders Use of b7rp1 antagonists in ige-mediated disorders

C - Chemistry, Metallurgy

12

N

C12N 15/12 (2006.01) A61K 38/17 (2006.01) A61K 39/395 (2006.01) A61P 31/12 (2006.01) A61P 37/06 (2006.01) A61P 37/08 (2006.01) C07K 14/705 (2006.01) C07K 14/725 (2006.01) C07K 16/28 (2006.01) C07K 19/00 (2006.01) G01N 33/53 (2006.01) G01N 33/68 (2006.01) A61K 48/00 (2006.01)

Patent

CA 2429599

Novel polypeptides which comprise a receptor-ligand pair involved in T-cell activation are disclosed. Nucleic acid molecules encoding said polypeptides, and vectors and host cells for expressing same are also disclosed. The polypeptides, or agonists and antagonists thereof, are used to treat T-cell mediated disorders.

La présente invention concerne de nouveaux polypeptides qui comprennent une paire récepteur-ligand impliquée dans l'activation des cellules T; des molécules d'acide nucléique codant ces polypeptides ainsi que des vecteurs et des cellules hôtes utiles pour exprimer ces derniers. Les polypeptides ou les agonistes et les antagonistes de ces derniers sont utilisés pour traiter les maladies induites par les cellules T.

Affiliated with

Also associated with

Rating

Use of b7rp1 antagonists in ige-mediated disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of b7rp1 antagonists in ige-mediated disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of b7rp1 antagonists in ige-mediated disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1880193